Benzodiazepine use during an IVF cycle and its impacts on miscarriage and other pregnancy outcomes.
Benzodiazepine use during IVF cycle not associated with miscarriage risk.
Benzodiazepine use during an IVF cycle and its impacts on miscarriage and other pregnancy outcomes.
STUDY QUESTION: How does benzodiazepine use during an IVF cycle affect pregnancy outcomes?
To compare the two groups, propensity score overlap weighting was applied to adjust for potential imbalances in confounders.
A retrospective cohort study was conducted using Korea's Health Insurance Review and Assessment (Health Insurance Review and Assessment) database between October 2017 and June 2024.
miscarriage risk was essentially unchanged with benzodiazepine use
Compared with non-users, benzodiazepine users had a lower prevalence of prior live birth and a higher prevalence of anxiety disorders, along with greater use of antidepressants before adjustment.
The absolute event rates of each outcome were as follows: (i) clinical pregnancy rate: 36.0% of users versus 35.7% of non-users, (ii) miscarriage rate: 14.9% versus 15.2%, (iii) live birth rate: 99.3% versus 99.3%, (iv) preterm birth rate: 13.3% versus 11.6%.
Benzodiazepine use was neither positively nor adversely associated with IVF pregnancy outcomes overall.
WHAT IS KNOWN ALREADY: Benzodiazepine use during oocyte retrieval, primarily with midazolam, and diazepam use at the time of embryo transfer (embryo transfer) have been reported to yield comparable procedural success rates to those of non-users, respectively.
However, these studies focus on exposure at a single time point, necessitating a more comprehensive investigation of benzodiazepine use across the entire IVF treatment period.